Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells.  CSFs in both human and murine systems have been identified and distinguished according to their activities.  For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies.  IL-3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies (when erythropoietin is added in combination). 
Because of its ability to stimulate the proliferation of a number of different cell types and to support the growth and proliferation of progenitor cells, IL-3 has potential for therapeutic use in restoring hematopoietic cells to normal amounts in those cases where the number of cells has been reduced due to diseases or to therapeutic treatments such as radiation and chemotherapy. 
Interleukin-3 (IL-3) is a hematopoietic growth factor which has the property of being able to promote the survival, growth and differentiation of hematopoietic cells.  Among the biological properties of IL-3 are the ability (a) to support the growth and differentiation of progenitor cells committed to all, or virtually all, blood cell lineages; (b) to interact with early multipotential stem cells; (c) to sustain the growth of pluripotent precursor cells; (d) to stimulate proliferation of chronic myelogenous leukemia (CML) cells; (e) to stimulate proliferation of mast cells, eosinophils and basophils; (f) to stimulate DNA synthesis by human acute myelogenous leukemia (AML) cells; (g) to prime cells for production of leukotrienes and histamines; (h) to induce leukocyte chemotaxis; and (i) to induce cell surface molecules needed for leukocyte adhesion. 
Mature human interleukin-3 (hIL-3) consists of 133 amino acids.  It has one disulfide bridge and two potential glycosylation sites (Yang, et al.,  CELL 47:3 (1986)). 
Murine IL-3 (mIL-3) was first identified by Ihle, et al.,  J. IMMUNOL.  126:2184 (1981) as a factor which induced expression of a T cell associated enzyme, 20-hydroxysteroid dehydrogenase.  The factor was purified to homogeneity and shown to regulate the growth and differentiation of numerous subclasses of early hematopoietic and lymphoid progenitor cells. 
In 1984, cDNA clones coding for murine IL-3 were isolated (Fung, et al.,  NATURE 307:233 (1984) and Yokota, et al.,  PROC.  NATL.  ACAD.  SCI.  USA 81:1070 (1984)).  The murine DNA sequence coded for a polypeptide of 166 amino acids including a putative signal peptide. 
The gibbon IL-3 sequence was obtained using a gibbon cDNA expression library.  The gibbon IL-3 sequence was then used as a probe against a human genomic library to obtain a human IL-3 sequence. 
Gibbon and human genomic DNA homologues of the murine IL-3 sequence were disclosed by Yang, et al.,  CELL 47:3 (1986).  The human sequence reported by Yang, et al.  included a serine residue at position 8 of the mature protein sequence.  Following this finding, others reported isolation of Pro.sup.8 hIL-3 cDNAs having proline at position 8 of the protein sequence.  Thus it appears that there may be two allelic forms of hIL-3. 
Dorssers, et al.,  GENE 55:115 (1987), found a clone from a human cDNA library which hybridized with mIL-3.  This hybridization was the result of the high degree of homology between the 3' noncoding regions of mIL-3 and hIL-3.  This cDNA coded for an hIL-3 (Pro.sup.8) sequence. 
U.S. Pat.  No.  4,877,729 and U.S. Pat.  No.  4,959,455 disclose human IL-3 and gibbon IL-3 cDNAs and the protein sequences for which they code.  The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence. 
Clark-Lewis, et al.,  SCIENCE 231:134 (1986) performed a functional analysis of murine IL-3 analogues synthesized with an automated peptide synthesizer.  The authors concluded that the stable tertiary structure of the complete molecule was required for full activity.  A study on the role of the disulfide bridges showed that replacement of all four cysteines by alanine gave a molecule with 1/500th the activity as the native molecule.  Replacement of two of the four Cys residues by Ala(Cys.sup.79, Cys.sup.140 .fwdarw. Ala.sup.79, Ala.sup.140) resulted in an increased activity.  The authors concluded that in murine IL-3 a single disulfide bridge is required between cysteines 17 and 80 to get biological activity that approximates physiological levels and that this structure probably stabilizes the tertiary structure of the protein to give a conformation that is optimal for function. ( Clark-Lewis, et al.,  PROC.  NATL.  ACAD.  SCI.  USA 85:7897 (1988)). 
International Patent Application (PCT) WO 88/00598 discloses gibbon- and human-like IL-3.  The hIL-3 contains a Ser.sup.8 .fwdarw. Pro.sup.8 replacement.  Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge, and to replace one or more amino acids at the glycosylation sites. 
EP-A-0275598 (WO 88/04691) illustrates that Ala.sup.1 can be deleted while retaining biological activity.  Some mutant hIL-3 sequences are provided, e.g., two double mutants, Ala.sup.1 .fwdarw. Asp.sup.1, Trp.sup.13 .fwdarw. Arg.sup.13 (pGB/IL-302) and Ala.sup.1 .fwdarw. Asp.sup.1, Met.sup.3 .fwdarw. Thr.sup.3 (pGB/IL-304) and one triple mutant Ala.sup.1 .fwdarw. Asp.sup.1, Leu.sup.9 .fwdarw. Pro.sup.9, Trp.sup.13 .fwdarw. Arg.sup.13 (pGB/IL-303). 
WO 88/05469 describes how deglycosylation mutants can be obtained and suggests mutants of Arg.sup.54 Arg.sup.55 and Arg.sup.108 Arg.sup.109 Lys.sup.110 might avoid proteolysis upon expression in Saccharomyces cerevisiae by KEX2 protease.  No mutated proteins are disclosed.  Glycosylation and the KEX2 protease activity are only important, in this context, upon expression in yeast. 
WO 88/06161 mentions various mutants which theoretically may be conformationally and antigenically neutral.  The only actually performed mutations are Met.sup.2 .fwdarw. Ile.sup.2 and Ile.sup.131 .fwdarw. Leu.sup.13 l. It is not disclosed whether the contemplated neutralities were obtained for these two mutations. 
WO 91/00350 discloses nonglycosylated hIL-3 analog proteins, for example, hIL-3 (Pro.sup.8 Asp.sup.1 5 Asp.sup.70), Met.sup.3 rhul-3 (Pro.sup.8 Asp.sup.15 Asp.sup.70); Thr.sup.4 rhuL-3 (Pro.sup.8 Asp.sup.15 Asp.sup.70)and Thr.sup.6 rhuIL-3 (Pro.sup.8 Asp.sup.15 Asp.sup.70).  It is said that these protein compositions do not exhibit certain adverse side effects associated with native hIL-3 such as urticaria resulting from infiltration of mast cells and lymphocytes into the dermis.  The disclosed analog hIL-3 proteins may have N termini at Met.sup.3, Thr.sup.4, or Thr.sup.6. 
WO 90/12874 discloses cysteine added variants (CAVs) of IL-3 which have at least one Cys residue substituted for a naturally occurring amino acid residue. 
U.S. Pat.  No.  4,810,643 discloses the DNA sequence encoding human G-CSF. 
WO 91/02754 discloses a fusion protein composed of GM-CSF and IL-3 which has increased biological activity compared to GM-CSF or IL-3 alone.  Also disclosed are nonglycosylated IL-3 and GM-CSF analog proteins as components of the fusion. 
WO 92/04455 discloses fusion proteins composed of IL-3 fused to a lymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9, IL-11, EPO and G-CSF.